Global Viral and Non-viral Vector Market Research Report 2024
상품코드:1623632
리서치사:QYResearch
발행일:2024년 12월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 바이러스 및 비바이러스 벡터 시장 규모는 2023년에 5억 5,185만 달러에 달했습니다.
시장은 2024-2030년 예측기간 동안 31.84%의 CAGR로 확대되어 2030년까지 35억 500만 달러에 달할 것으로 예측됩니다.
북미의 바이러스 및 비바이러스 벡터 시장 규모는 2023년에 2억 3,200만 달러에 달했습니다. 시장은에서 2024년부터 2030년 예측기간에 31%의 CAGR로 확대되어 2030년에는 14억 2,300만 달러에 달할 것으로 예측됩니다.
아시아태평양의 바이러스 및 비바이러스 벡터 시장 규모는 2023년에 1억 4,100만 달러에 달했습니다. 시장은 2024년부터 2030년 예측기간 동안 33.67%의 CAGR로 확대되어 2030년에는 9억 8,300만 달러에 달할 것으로 예측됩니다.
바이러스 및 비바이러스 벡터의 주요 세계 기업에는 Lonza, Thermo Fisher Scientific, VectorBuilder, GenScript Biotech, Gene Chem, Revvity 등이 있습니다. 2023년에는 세계 상위 5개 벤더가 매출의 약 62.03%를 차지하고 있습니다.
세계의 바이러스 및 비바이러스 벡터 시장에 대해 조사했으며, 시장 개요와 함께 유형별, 용도별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.
목차
제1장 보고서 개요
조사 범위
유형별 시장 분석
용도별 시장
가정과 제한
조사 목적
대상 연도
제2장 세계의 성장 동향
세계의 바이러스 및 비바이러스 벡터 시장 전망(2019-2030년)
세계의 바이러스 및 비바이러스 벡터 성장 동향, 지역별
바이러스 및 비바이러스 벡터 시장 역학
제3장 주요 진출 기업에 의한 경쟁 구도
제4장 바이러스 및 비바이러스 벡터 내역 데이터, 유형별
세계의 바이러스 및 비바이러스 벡터 시장 규모 실적, 유형별(2019-2024년)
세계의 바이러스 및 비바이러스 벡터 시장 규모 예측, 유형별(2025-2030년)
제5장 바이러스 및 비바이러스 벡터 내역 데이터, 용도별
세계의 바이러스 및 비바이러스 벡터 시장 규모 실적, 용도별(2019-2024년)
세계의 바이러스 및 비바이러스 벡터 시장 규모 예측, 용도별(2025-2030년)
제6장 북미
제7장 유럽
제8장 아시아태평양
제9장 남미
제10장 중동 및 아프리카
제11장 주요인 기업 로파일
Thermo Fisher Scientific
Lonza
Azenta Life Sciences
Revvity
VectorBuilder
Takara Bio
GenScript Biotech
Gene Chem
Geno Meditech
PackGene Biotech
VIROVEK
OriGen
Vector BioLabs
제12장 애널리스트의 견해/결론
제13장 부록
KSM
영문 목차
영문목차
The global Viral and Non-viral Vector market was valued at US$ 551.85 million in 2023 and is anticipated to reach US$ 3505 million by 2030, witnessing a CAGR of 31.84% during the forecast period 2024-2030.
North American market for Viral and Non-viral Vector is estimated to increase from $ 232 million in 2023 to reach $ 1423million by 2030, at a CAGR of 31% during the forecast period of 2024 through 2030.
Asia-Pacific market for Viral and Non-viral Vector is estimated to increase from $ 141 million in 2023 to reach $ 983 million by 2030, at a CAGR of 33.67% during the forecast period of 2024 through 2030.
The major global companies of Viral and Non-viral Vector include Lonza, Thermo Fisher Scientific, VectorBuilder, GenScript Biotech, Gene Chem, Revvity, etc. In 2023, the world's top five vendors accounted for approximately 62.03 % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Viral and Non-viral Vector, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral and Non-viral Vector.
The Viral and Non-viral Vector market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral and Non-viral Vector market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral and Non-viral Vector companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Thermo Fisher Scientific
Lonza
Azenta Life Sciences
Revvity
VectorBuilder
Takara Bio
GenScript Biotech
Gene Chem
Geno Meditech
PackGene Biotech
VIROVEK
OriGen
Vector BioLabs
Segment by Type
AAV
Lentiviruses
Retroviruses
Adenoviruses
DNA Plasmids
Others
Segment by Application
Pharmaceutical and Biopharmaceutical Companies
Academics and Research Institutes
Others
By Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe
South America
Brazil
Rest of South America
Middle East & Africa
Middle East
Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral and Non-viral Vector company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral and Non-viral Vector Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 AAV
1.2.3 Lentiviruses
1.2.4 Retroviruses
1.2.5 Adenoviruses
1.2.6 DNA Plasmids
1.3 Market by Application
1.3.1 Global Viral and Non-viral Vector Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical and Biopharmaceutical Companies
1.3.3 Academics and Research Institutes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral and Non-viral Vector Market Perspective (2019-2030)
2.2 Global Viral and Non-viral Vector Growth Trends by Region
2.2.1 Global Viral and Non-viral Vector Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Viral and Non-viral Vector Historic Market Size by Region (2019-2024)
2.2.3 Viral and Non-viral Vector Forecasted Market Size by Region (2025-2030)
2.3 Viral and Non-viral Vector Market Dynamics
2.3.1 Viral and Non-viral Vector Industry Trends
2.3.2 Viral and Non-viral Vector Market Drivers
2.3.3 Viral and Non-viral Vector Market Challenges
2.3.4 Viral and Non-viral Vector Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral and Non-viral Vector Players by Revenue
3.1.1 Global Top Viral and Non-viral Vector Players by Revenue (2019-2024)
3.1.2 Global Viral and Non-viral Vector Revenue Market Share by Players (2019-2024)
3.2 Global Viral and Non-viral Vector Market by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Viral and Non-viral Vector Revenue
3.4 Global Viral and Non-viral Vector Market Concentration Ratio
3.4.1 Global Viral and Non-viral Vector Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral and Non-viral Vector Revenue in 2023
3.5 Global Key Players of Viral and Non-viral Vector Head office and Area Served
3.6 Global Key Players of Viral and Non-viral Vector, Product
3.7 Global Key Players of Viral and Non-viral Vector, Founded Date
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral and Non-viral Vector Breakdown Data by Type
4.1 Global Viral and Non-viral Vector Historic Market Size by Type (2019-2024)
4.2 Global Viral and Non-viral Vector Forecasted Market Size by Type (2025-2030)
5 Viral and Non-viral Vector Breakdown Data by Application
5.1 Global Viral and Non-viral Vector Historic Market Size by Application (2019-2024)
5.2 Global Viral and Non-viral Vector Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Viral and Non-viral Vector Market Size (2019-2030)
6.2 North America Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Viral and Non-viral Vector Market Size by Country (2019-2024)
6.4 North America Viral and Non-viral Vector Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
6.7 Mexico
7 Europe
7.1 Europe Viral and Non-viral Vector Market Size (2019-2030)
7.2 Europe Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Viral and Non-viral Vector Market Size by Country (2019-2024)
7.4 Europe Viral and Non-viral Vector Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Spain
8 Asia-Pacific
8.1 Asia-Pacific Viral and Non-viral Vector Market Size (2019-2030)
8.2 Asia-Pacific Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Viral and Non-viral Vector Market Size by Region (2019-2024)
8.4 Asia-Pacific Viral and Non-viral Vector Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 South America
9.1 South America Viral and Non-viral Vector Market Size (2019-2030)
9.2 South America Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 South America Viral and Non-viral Vector Market Size by Country (2019-2024)
9.4 South America Viral and Non-viral Vector Market Size by Country (2025-2030)
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral and Non-viral Vector Market Size (2019-2030)
10.2 Middle East & Africa Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Viral and Non-viral Vector Market Size by Country (2019-2024)
10.4 Middle East & Africa Viral and Non-viral Vector Market Size by Country (2025-2030)
10.5 Middle East
10.6 Africa
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Viral and Non-viral Vector Introduction
11.1.4 Thermo Fisher Scientific Revenue in Viral and Non-viral Vector Business (2019-2024)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Viral and Non-viral Vector Introduction
11.2.4 Lonza Revenue in Viral and Non-viral Vector Business (2019-2024)
11.2.5 Lonza Recent Development
11.3 Azenta Life Sciences
11.3.1 Azenta Life Sciences Company Details
11.3.2 Azenta Life Sciences Business Overview
11.3.3 Azenta Life Sciences Viral and Non-viral Vector Introduction
11.3.4 Azenta Life Sciences Revenue in Viral and Non-viral Vector Business (2019-2024)
11.3.5 Azenta Life Sciences Recent Development
11.4 Revvity
11.4.1 Revvity Company Details
11.4.2 Revvity Business Overview
11.4.3 Revvity Viral and Non-viral Vector Introduction
11.4.4 Revvity Revenue in Viral and Non-viral Vector Business (2019-2024)
11.5 VectorBuilder
11.5.1 VectorBuilder Company Details
11.5.2 VectorBuilder Business Overview
11.5.3 VectorBuilder Viral and Non-viral Vector Introduction
11.5.4 VectorBuilder Revenue in Viral and Non-viral Vector Business (2019-2024)
11.5.5 VectorBuilder Recent Development
11.6 Takara Bio
11.6.1 Takara Bio Company Details
11.6.2 Takara Bio Business Overview
11.6.3 Takara Bio Viral and Non-viral Vector Introduction
11.6.4 Takara Bio Revenue in Viral and Non-viral Vector Business (2019-2024)
11.6.5 Takara Bio Recent Development
11.7 GenScript Biotech
11.7.1 GenScript Biotech Company Details
11.7.2 GenScript Biotech Business Overview
11.7.3 GenScript Biotech Viral and Non-viral Vector Introduction
11.7.4 GenScript Biotech Revenue in Viral and Non-viral Vector Business (2019-2024)
11.7.5 GenScript Biotech Recent Development
11.8 Gene Chem
11.8.1 Gene Chem Company Details
11.8.2 Gene Chem Business Overview
11.8.3 Gene Chem Viral and Non-viral Vector Introduction
11.8.4 Gene Chem Revenue in Viral and Non-viral Vector Business (2019-2024)
11.9 Geno Meditech
11.9.1 Geno Meditech Company Details
11.9.2 Geno Meditech Business Overview
11.9.3 Geno Meditech Viral and Non-viral Vector Introduction
11.9.4 Geno Meditech Revenue in Viral and Non-viral Vector Business (2019-2024)
11.10 PackGene Biotech
11.10.1 PackGene Biotech Company Details
11.10.2 PackGene Biotech Business Overview
11.10.3 PackGene Biotech Viral and Non-viral Vector Introduction
11.10.4 PackGene Biotech Revenue in Viral and Non-viral Vector Business (2019-2024)
11.11 VIROVEK
11.11.1 VIROVEK Company Details
11.11.2 VIROVEK Business Overview
11.11.3 VIROVEK Viral and Non-viral Vector Introduction
11.11.4 VIROVEK Revenue in Viral and Non-viral Vector Business (2019-2024)
11.11.5 VIROVEK Recent Development
11.12 OriGen
11.12.1 OriGen Company Details
11.12.2 OriGen Business Overview
11.12.3 OriGen Viral and Non-viral Vector Introduction
11.12.4 OriGen Revenue in Viral and Non-viral Vector Business (2019-2024)
11.13 Vector BioLabs
11.13.1 Vector BioLabs Company Details
11.13.2 Vector BioLabs Business Overview
11.13.3 Vector BioLabs Viral and Non-viral Vector Introduction
11.13.4 Vector BioLabs Revenue in Viral and Non-viral Vector Business (2019-2024)
